Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has scheduled its third quarter 2024 financial results announcement for November 12, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a business update. The conference call will be accessible via phone (1.877.407.0789) with Conference ID 13749428, and a webcast replay will be available on the company's website.
Longeveron (NASDAQ: LGVN), una compagnia biotecnologica specializzata in medicina rigenerativa in fase clinica, ha programmato l'annuncio dei suoi risultati finanziari per il terzo trimestre 2024 per il 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sulle attività. La conferenza telefonica sarà accessibile telefonicamente (1.877.407.0789) con ID Conferenza 13749428, e la registrazione del webcast sarà disponibile sul sito web dell'azienda.
Longeveron (NASDAQ: LGVN), una empresa de biotecnología en etapa clínica especializada en medicina regenerativa, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 12 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET el mismo día para discutir los resultados y proporcionar una actualización sobre el negocio. La conferencia telefónica será accesible por teléfono (1.877.407.0789) con el ID de Conferencia 13749428, y una grabación del webcast estará disponible en el sitio web de la empresa.
롱기버론 (NASDAQ: LGVN), 임상 단계의 재생 의학 생명공학 회사,는 2024년 11월 12일 시장 종료 후 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 동일한 날 오후 4시 30분 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 것입니다. 컨퍼런스 콜은 전화 (1.877.407.0789)를 통해 접근 가능하며, 회의 ID는 13749428입니다. 웹캐스트 재생은 회사 웹사이트에서 이용할 수 있습니다.
Longeveron (NASDAQ: LGVN), une société de biotechnologie spécialisée dans la médecine régénérative en phase clinique, a programmé l'annonce de ses résultats financiers du troisième trimestre 2024 pour le 12 novembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webcast le même jour à 16h30 ET pour discuter des résultats et fournir une mise à jour sur les activités. La conférence téléphonique sera accessible par téléphone (1.877.407.0789) avec l'ID de conférence 13749428, et une rediffusion du webcast sera disponible sur le site web de l'entreprise.
Longeveron (NASDAQ: LGVN), ein biopharmazeutisches Unternehmen im klinischen Stadium für regenerative Medizin, hat die Ankündigung seiner Finanzergebnisse für das dritte Quartal 2024 für den 12. November 2024, nach Börsenschluss, angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen und ein Update zum Geschäft zu geben. Die Telefonkonferenz ist telefonisch (1.877.407.0789) mit der Konferenz-ID 13749428 erreichbar, und eine Aufzeichnung des Webcasts wird auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference Call Details:
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13749428 |
| Call me™ Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s Disease (AD), and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When will Longeveron (LGVN) report Q3 2024 earnings?
What time is Longeveron's (LGVN) Q3 2024 earnings call?
How can I access Longeveron's (LGVN) Q3 2024 earnings call?
